Statement of Changes in Beneficial Ownership (4)
June 12 2020 - 04:03PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Zoghbi Huda Y |
2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC.
[
REGN
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
777 OLD SAW MILL RIVER ROAD |
3. Date of Earliest Transaction
(MM/DD/YYYY)
6/10/2020 |
(Street)
TARRYTOWN, NY 10591
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 6/10/2020 | | M(1) | | 1706 | A | $391.92 | 2349 | D | |
Common Stock | 6/10/2020 | | S(1) | | 149 | D | $606.64 (2) | 2200 | D | |
Common Stock | 6/10/2020 | | S(1) | | 251 | D | $607.64 (3) | 1949 | D | |
Common Stock | 6/10/2020 | | S(1) | | 330 | D | $608.62 (4) | 1619 | D | |
Common Stock | 6/10/2020 | | S(1) | | 161 | D | $609.48 (5) | 1458 | D | |
Common Stock | 6/10/2020 | | S(1) | | 202 | D | $610.41 (6) | 1256 | D | |
Common Stock | 6/10/2020 | | S(1) | | 164 | D | $611.46 (7) | 1092 | D | |
Common Stock | 6/10/2020 | | S(1) | | 265 | D | $612.52 (8) | 827 | D | |
Common Stock | 6/10/2020 | | S(1) | | 5 | D | $613.03 | 822 | D | |
Common Stock | 6/10/2020 | | S(1) | | 80 | D | $615.28 | 742 | D | |
Common Stock | 6/10/2020 | | S(1) | | 99 | D | $616.19 | 643 | D | |
Common Stock | 6/11/2020 | | M(1) | | 1706 | A | $391.92 | 2349 | D | |
Common Stock | 6/11/2020 | | S(1) | | 1706 | D | $625.0 | 643 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Non-Qualified Stock Option (right to buy) | $391.92 | 6/10/2020 | | M (1) | | | 1706 | (9) | 9/9/2026 | Common Stock | 1706 | $0.0 | 8529 | D | |
Non-Qualified Stock Option (right to buy) | $391.92 | 6/11/2020 | | M (1) | | | 1706 | (9) | 9/9/2026 | Common Stock | 1706 | $0.0 | 6823 | D | |
Explanation of Responses: |
(1) | Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). |
(2) | Represents volume-weighted average price of sales of 149 shares of Company stock on June 10, 2020 at prices ranging from $606.23 to $606.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 10, 2020 at each separate price. |
(3) | Represents volume-weighted average price of sales of 251 shares of Company stock on June 10, 2020 at prices ranging from $607.02 to $607.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 10, 2020 at each separate price. |
(4) | Represents volume-weighted average price of sales of 330 shares of Company stock on June 10, 2020 at prices ranging from $608.15 to $608.9. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 10, 2020 at each separate price. |
(5) | Represents volume-weighted average price of sales of 161 shares of Company stock on June 10, 2020 at prices ranging from $609.31 to $609.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 10, 2020 at each separate price. |
(6) | Represents volume-weighted average price of sales of 202 shares of Company stock on June 10, 2020 at prices ranging from $610.18 to $610.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 10, 2020 at each separate price. |
(7) | Represents volume-weighted average price of sales of 164 shares of Company stock on June 10, 2020 at prices ranging from $611.06 to $611.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 10, 2020 at each separate price. |
(8) | Represents volume-weighted average price of sales of 265 shares of Company stock on June 10, 2020 at prices ranging from $612.12 to $612.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 10, 2020 at each separate price. |
(9) | The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Zoghbi Huda Y 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591 | X |
|
|
|
Signatures
|
Huda Y. Zoghbi | | 6/11/2020 |
**Signature of Reporting Person | Date |
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Mar 2023 to Mar 2024